<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015352</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-Aza-Epo-2008-01</org_study_id>
    <nct_id>NCT01015352</nct_id>
  </id_info>
  <brief_title>Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)</brief_title>
  <official_title>A Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to treat low-risk MDS patients,who are dependent on red-blood cell
      transfusion due to disease-related anemia, and who have a proven resistance towards treatment
      with erythropoetin-stimulating agents (ESA). The study randomizes patients to receive a
      treatment with the demethylating agent 5-azacytidine alone or in combination with an ESA. The
      study thus evaluates, if efficacy of 5-azacytidine, notably on the red-blood cell
      transfusion-dependence is comparable/inferior to a combination treatment with azacitidine and
      an ESA (that is if 5-azacytidine can overcome the resistance towards ESA). Being a phase II
      study, the study assesses, duration of erythroid response, overall survival and time to
      progression as well as toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS
      Low-risk and Intermediate-1 MDS Patients, Resistant to ESA

      The Primary Endpoint of this study is to determine the major erythroid response rate after 6
      courses, assessed according to IWG 2000 criteria.

      The Secondary Endpoints are to determine the percentage of major HI-E and minor HI-E after 4
      and 6 courses according to IWG 2000, the HI-E IWG 2006 criteria, the duration of erythroid
      response, the red blood cell transfusion independence at 4 and 6 months, the overall survival
      and time to IPSS progression and the toxicity (NCI-CTAE).

      The trial will enroll 98 patients (49 patients per arm)

      Treatment in arm A:

      Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses Dosing of each
      subsequent course will be adapted according to extrahematological toxicity and cytopenias.

      In responders after 6 courses of azacitidine according to IWG 2000 criteria (both minor and
      major erythroid responses of HI-E) 12 identical additional maintenance courses will be
      delivered every 28 days, unless relapse occurs (according to IWG 2000 criteria).

      Treatment in arm B:

      • Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses.

      (dosing of each subsequent course will be adapted according to extra hematological toxicity
      and cytopenias) AND

      • Epoetin beta : 60000U weekly SQ injections Dosing of epoetin beta will be adapted according
      to current ASH-ASCO guidelines and black box warning of epoetin beta. Epoetin beta therapy
      may therefore be interrupted, in case of response to azacitidine, as soon as a hemoglobin
      level of 12g/dl is achieved on two sequential bimonthly blood count measurements.

      A 40% dose reduction of epoetin beta will be required if:

        -  Hb level rise of 1 g/dl is observed within two weeks

        -  Hb level exceeds 11g/dl

      In responders after 6 courses of azacitidine + epoetin beta, according to IWG 2000 criteria
      (both minor and major erythroid responses of HI-E) 12 identical additional maintenance
      courses of azacitidine will be delivered every 28 days, unless relapse occurs (according to
      IWG 2000 criteria) Epoetin beta will be administered as described above.

      In both arms, each subsequent course will be delivered

        -  In absence of persistent grade &gt;2 non-hematological toxicity

        -  In absence of rehospitalisation for severe bleeding, infection or febrile neutropenia
           and non-hematological toxicity following the previous course

        -  If neutrophil counts are &gt; 1G/l or &gt; 50% of baseline neutrophil counts

        -  If platelets are &gt; 75G/l or &gt; 50% of baseline platelets counts

      In case of persistent cytopenia, blood counts will be at least checked every 2 weeks, and the
      next course delayed until resolution of cytopenia, as defined above.

      In case of persistence of cytopenia beyond day 56 of the preceding course, an new evaluation
      of the disease, using clinical examination, blood and bone marrow examinations +/-
      cytogenetics will be mandatory before eventually pursuing azacitidine at lower dosing levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the major erythroid response rate after 6 courses, assessed according to IWG 2000 criteria</measure>
    <time_frame>after 6 courses of treatment in the respective treatment arm</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree and duration of erythroid response (including red blood cell transfusion independence),overall survival and time to progression and toxicity</measure>
    <time_frame>after 4 and 6 months of treatment until the end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses and 12 additional maintenance courses in responders.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azacitidine: 75mg/sqm SQ per day for 5 days every 28 days for 6 courses AND
Epoetin beta : 60000U weekly SQ injections (to be adapted according to Hb as described above)
12 additional maintenance courses are planned in responders</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine 75mg/sqm SQ per day for 5 days every 28 days</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Vidaza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin beta</intervention_name>
    <description>Epoetin beta : 60000U weekly SQ injections
NeoRecormon®</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Epoetin beta : 60000U weekly SQ injections</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        MDS defined as

          -  RCMD, RA with or without ring sideroblasts

          -  RAEB 1, or CMML 1, if WBC &lt; 13 G /l according to the WHO classification

          -  with a low or int-1 IPSS score AND

          -  primary or secondary resistance to epoetin alpha/ beta (&gt; 60000 U/w) or darbepoetin (&gt;
             250ug/w), administered for at least 12 weeks

          -  requirement of RBC transfusions &gt; 4 U in the previous 8 weeks

          -  Aged 18 years or more

          -  Adequate contraception, if relevant

          -  Negative pregnancy test if relevant

          -  Written Informed consent

          -  Ability to participate to a clinical trial and adhere to study procedures

          -  Health insurance

        Exclusion Criteria:

          -  Therapy-related MDS (after chemo- or radiotherapy for a previous neoplasm or immune
             disorder)

          -  Patients with a planned allogeneic bone marrow transplantation

          -  Creatininemia &gt;1.5 upper normal value or estimated Ccr less than 30ml/mn

          -  ALAT and ASAT &gt;2.5 upper normal value

          -  Bilirubin &gt;2N, except unconjugated hyperbilirubinemia due to MDS-related
             dyserythropoiesis

          -  Heart failure NYHA &gt; II

          -  Known allergy to mannitol

          -  Other tumor, unstable for the last three years, except in situ uterine carcinoma or
             basal skin tumor

          -  ECOG &gt; 2

          -  Life expectancy less than 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simone Boehrer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Francophone des Myélodysplasies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claude Gardin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Francophone des Myélodysplasies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Boulogne Sur Mer</name>
      <address>
        <city>Boulogne Sur Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Clémenceau</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital kremlin Bicêtre</name>
      <address>
        <city>Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Source</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Maréchal Joffre</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean-Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gfmgroup.org</url>
    <description>(Website of the french group of MDS)</description>
  </link>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

